2.50
Hdl Handle:
http://hdl.handle.net/10755/165604
Category:
Abstract
Type:
Presentation
Title:
Investigational Use of the Amino Acid Glutamine as a Neuroprotectant
Author(s):
Williamson, Judith
Author Details:
Judith Williamson, OSF Saint Anthony Medical Center, Rockford, Illinois, USA
Abstract:
Introduction: Paclitaxel (Taxol(r)) is a chemotherapeutic agent used for multiple malignancies. Transient treatment induced grade 3 or 4 arthralgias and myalgias may be experienced by 75% of the patients. Symptomatic treatment will rest and non-steroidal anti-inflammatory analgesics may be less than optimal. Glutamine is an amino acid formed and stored in the skeletal muscles and lungs. It functions as a nitrogen donor for various neural synaptic pathways, as a precursor in both nucleic acid synthesis and nucleotide synthesis, as a part of the acid-base balancing system, as a precursor for various neurotransmitters, and as an energy source for the cells of the immune system. Glutamine also helps regulate glycogen synthesis and is an important substrate for cells of the intestinal mucosa. When the body experiences metabolic stress or catabolic disease, glutamine is freely released by the skeletal muscles and causes a decrease in intracellular glutamine. Oral glutamine has been successfully used to treat Paclitaxel (Taxol) induced myalgias and arthralgias in a small number of patients as demonstrated by Savarese et al. at the University of Massachusetts. Glutamine can minimize mucositis/stomatitis in the GI tract with radiation therapy as reported by Loprinzi et al. at the University of Minnesota. Objectives: To determine if the use of oral glutamine after chemotherapy prevents or minimizes the development of myalgias, arthralgias, and peripheral neuropathies in patients receiving Paclitaxel (Taxol). The Study: Twenty patients meeting the eligibility criteria of no prior arthralgias, myalgias, or peripheral neuropathies; receiving a dose of paclitaxel (Taxol) greater that 175mg/m2; no previous history of diabetes or circulatory disease; being 18 years of age or older; good performance status within the guidelines for receiving chemotherapy; a life expectancy of longer than two months, currently not being pregnant; and not now taking a Glutamine product. Results will be reviewed weekly per completion of a Likert scale of a patient self-assessment of symptoms. Every three weeks the physician or nurse practitioner will complete a neurotoxicity assessment, a physical examination, and pertinent laboratory work. The patient will sign an informed consent prior to being placed on the study. Results will be reviewed at six months to determine if the study should be expanded. Treatment Plan: Patients receiving Paclitaxel (Taxol) doses of greater than 175mg/m2 will be randomized to either Glutamine 10 GMS. by mouth three times a day for five days after chemotherapy or use of the standard non-steroidal anti-inflammatory analgesics and rest. Glutamine will be provided for the patients through the Center for Cancer Care to ensure they will be receiving pure product. Adverse events occurring with the use of Glutamine are not expected; should they occur, they will be reported per the same guidelines of any adverse event to a research participant. OSF Saint Anthony Medical Center IRB has approved the study and the recruitment of participants has begun. Preliminary data should be available to be reported in three months.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2002
Conference Name:
27th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Washington, D.C., USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleInvestigational Use of the Amino Acid Glutamine as a Neuroprotectanten_GB
dc.contributor.authorWilliamson, Judithen_US
dc.author.detailsJudith Williamson, OSF Saint Anthony Medical Center, Rockford, Illinois, USAen_US
dc.identifier.urihttp://hdl.handle.net/10755/165604-
dc.description.abstractIntroduction: Paclitaxel (Taxol(r)) is a chemotherapeutic agent used for multiple malignancies. Transient treatment induced grade 3 or 4 arthralgias and myalgias may be experienced by 75% of the patients. Symptomatic treatment will rest and non-steroidal anti-inflammatory analgesics may be less than optimal. Glutamine is an amino acid formed and stored in the skeletal muscles and lungs. It functions as a nitrogen donor for various neural synaptic pathways, as a precursor in both nucleic acid synthesis and nucleotide synthesis, as a part of the acid-base balancing system, as a precursor for various neurotransmitters, and as an energy source for the cells of the immune system. Glutamine also helps regulate glycogen synthesis and is an important substrate for cells of the intestinal mucosa. When the body experiences metabolic stress or catabolic disease, glutamine is freely released by the skeletal muscles and causes a decrease in intracellular glutamine. Oral glutamine has been successfully used to treat Paclitaxel (Taxol) induced myalgias and arthralgias in a small number of patients as demonstrated by Savarese et al. at the University of Massachusetts. Glutamine can minimize mucositis/stomatitis in the GI tract with radiation therapy as reported by Loprinzi et al. at the University of Minnesota. Objectives: To determine if the use of oral glutamine after chemotherapy prevents or minimizes the development of myalgias, arthralgias, and peripheral neuropathies in patients receiving Paclitaxel (Taxol). The Study: Twenty patients meeting the eligibility criteria of no prior arthralgias, myalgias, or peripheral neuropathies; receiving a dose of paclitaxel (Taxol) greater that 175mg/m2; no previous history of diabetes or circulatory disease; being 18 years of age or older; good performance status within the guidelines for receiving chemotherapy; a life expectancy of longer than two months, currently not being pregnant; and not now taking a Glutamine product. Results will be reviewed weekly per completion of a Likert scale of a patient self-assessment of symptoms. Every three weeks the physician or nurse practitioner will complete a neurotoxicity assessment, a physical examination, and pertinent laboratory work. The patient will sign an informed consent prior to being placed on the study. Results will be reviewed at six months to determine if the study should be expanded. Treatment Plan: Patients receiving Paclitaxel (Taxol) doses of greater than 175mg/m2 will be randomized to either Glutamine 10 GMS. by mouth three times a day for five days after chemotherapy or use of the standard non-steroidal anti-inflammatory analgesics and rest. Glutamine will be provided for the patients through the Center for Cancer Care to ensure they will be receiving pure product. Adverse events occurring with the use of Glutamine are not expected; should they occur, they will be reported per the same guidelines of any adverse event to a research participant. OSF Saint Anthony Medical Center IRB has approved the study and the recruitment of participants has begun. Preliminary data should be available to be reported in three months.en_GB
dc.date.available2011-10-27T12:21:41Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:21:41Z-
dc.conference.date2002en_US
dc.conference.name27th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationWashington, D.C., USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.